Biomerica, Inc. - Common Stock (BMRA)
Healthcare › In Vitro & In Vivo Diagnostic Substances
Price History
Feb 9, 2026 — Mar 25, 2026Investment Snapshot
- P/B of 1.47 — trading near book value
- Piotroski F-Score 4/9 — moderate financial health
- Loss-making — negative ROE of -77.4%
Biomerica, Inc. - Common Stock (BMRA) is a Healthcare company operating in In Vitro & In Vivo Diagnostic Substances, listed on the NASDAQ , with a market capitalisation of $7 million . Key value metrics: P/B ratio 1.47, Piotroski F-Score 4 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Biomerica, Inc. - Common Stock — Fundamental Analysis Summary
On financial health, BMRA shows a moderate Piotroski F-Score of 4/9, and negative return on equity of -77.4% (sector average: -19.8%), and manageable leverage with a debt-to-equity ratio of 0.36.
StockPik's composite Value Score for BMRA is 55/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
BMRA reports a thin gross margin of 17.4% (sector average: 33.5%) and a negative operating margin of -87.8%.
BMRA shows revenue declining at 2% year-over-year, with earnings growing at 17%.